266 related articles for article (PubMed ID: 25715385)
1. Patterns of oral anticoagulants use in atrial fibrillation.
Brais C; Larochelle J; Turgeon M; Tousignant A; Blais L; Perreault S; Farand P; Letemplier G; Beauchesne M
J Popul Ther Clin Pharmacol; 2015; 22(1):e90-5. PubMed ID: 25715385
[TBL] [Abstract][Full Text] [Related]
2. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.
Zalesak M; Siu K; Francis K; Yu C; Alvrtsyan H; Rao Y; Walker D; Sander S; Miyasato G; Matchar D; Sanchez H
Circ Cardiovasc Qual Outcomes; 2013 Sep; 6(5):567-74. PubMed ID: 23922182
[TBL] [Abstract][Full Text] [Related]
3. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.
Chan KE; Edelman ER; Wenger JB; Thadhani RI; Maddux FW
Circulation; 2015 Mar; 131(11):972-9. PubMed ID: 25595139
[TBL] [Abstract][Full Text] [Related]
4. Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation.
Steinberg BA; Holmes DN; Piccini JP; Ansell J; Chang P; Fonarow GC; Gersh B; Mahaffey KW; Kowey PR; Ezekowitz MD; Singer DE; Thomas L; Peterson ED; Hylek EM;
J Am Heart Assoc; 2013 Nov; 2(6):e000535. PubMed ID: 24275632
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation--a real patient data analysis in a Hong Kong teaching hospital.
Chang AM; Ho JC; Yan BP; Yu CM; Lam YY; Lee VW
Clin Cardiol; 2013 May; 36(5):280-5. PubMed ID: 23494609
[TBL] [Abstract][Full Text] [Related]
6. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial.
Oldgren J; Alings M; Darius H; Diener HC; Eikelboom J; Ezekowitz MD; Kamensky G; Reilly PA; Yang S; Yusuf S; Wallentin L; Connolly SJ;
Ann Intern Med; 2011 Nov; 155(10):660-7, W204. PubMed ID: 22084332
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
Chevalier J; Delaitre O; Hammès F; de Pouvourville G
Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
Graham DJ; Reichman ME; Wernecke M; Zhang R; Southworth MR; Levenson M; Sheu TC; Mott K; Goulding MR; Houstoun M; MaCurdy TE; Worrall C; Kelman JA
Circulation; 2015 Jan; 131(2):157-64. PubMed ID: 25359164
[TBL] [Abstract][Full Text] [Related]
9. Dabigatran for stroke prevention in all patients with atrial fibrillation?
Hunchuck JE; Lake JD
Pharmacotherapy; 2011 Aug; 31(8):725-8. PubMed ID: 21923597
[No Abstract] [Full Text] [Related]
10. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis.
Hijazi Z; Hohnloser SH; Oldgren J; Andersson U; Connolly SJ; Eikelboom JW; Ezekowitz MD; Reilly PA; Siegbahn A; Yusuf S; Wallentin L
Circulation; 2014 Mar; 129(9):961-70. PubMed ID: 24323795
[TBL] [Abstract][Full Text] [Related]
11. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.
Abraham NS; Singh S; Alexander GC; Heien H; Haas LR; Crown W; Shah ND
BMJ; 2015 Apr; 350():h1857. PubMed ID: 25910928
[TBL] [Abstract][Full Text] [Related]
12. Effect of dabigatran on referrals to and switching from warfarin in two academic anticoagulation management services.
Atay JK; Fanikos J; Barnes GD; Ehle M; Coatney J; Piazza G; Froehlich JB; Goldhaber SZ
Am J Cardiol; 2013 Aug; 112(3):387-9. PubMed ID: 23647794
[TBL] [Abstract][Full Text] [Related]
13. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL
Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181
[TBL] [Abstract][Full Text] [Related]
14. Atrial fibrillation in 2010: advances in treatment and management.
Connolly SJ
Nat Rev Cardiol; 2011 Feb; 8(2):67-8. PubMed ID: 21270842
[TBL] [Abstract][Full Text] [Related]
15. Risk of bleeding with dabigatran in atrial fibrillation.
Hernandez I; Baik SH; Piñera A; Zhang Y
JAMA Intern Med; 2015 Jan; 175(1):18-24. PubMed ID: 25365537
[TBL] [Abstract][Full Text] [Related]
16. Intracranial hemorrhage mortality in atrial fibrillation patients treated with dabigatran or warfarin.
Alonso A; Bengtson LG; MacLehose RF; Lutsey PL; Chen LY; Lakshminarayan K
Stroke; 2014 Aug; 45(8):2286-91. PubMed ID: 24994722
[TBL] [Abstract][Full Text] [Related]
17. Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation.
Eikelboom JW; Connolly SJ; Hart RG; Wallentin L; Reilly P; Oldgren J; Yang S; Yusuf S
J Am Coll Cardiol; 2013 Sep; 62(10):900-8. PubMed ID: 23770182
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.
Kamel H; Johnston SC; Easton JD; Kim AS
Stroke; 2012 Mar; 43(3):881-3. PubMed ID: 22308255
[TBL] [Abstract][Full Text] [Related]
19. Dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Edwards DB; Silverberg J
Ann Intern Med; 2011 Apr; 154(8):570; author reply 570-1. PubMed ID: 21502658
[No Abstract] [Full Text] [Related]
20. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Mantha S; Ansell J
Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]